ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance

SAN CLEMENTE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2024. Fourth Quarter 2024 Results Fourth quarter 2024 revenue was $629.8 million, as compared to $587.9 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2024 was $227.3 million, as compared to $171.6 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2024 was 36.1%, as compared to 29.2% in the same period in the prior year. GAAP net loss for the fourth quarter of 2024 was $(23.8) million, or $(0.97) per diluted share, as compared to GAAP net loss of $(17.1) million, or $(0.71) per diluted share, for the fourth quarter of 2023. Adjusted diluted earnings per share for the fourth quarter of 2024 was $2.11 as compared to $1.57 for the fourth quarter of 2023. Adjusted EBITDA was $105.5 million for the fourth quarter of 2024 as compared to $86.3 million for the fourth quarter of 2023. Adjusted EBITDA and adjusted diluted earnings per share are measures calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information following the financial statements herein for further discussion and reconciliations of these measures to GAAP measures. Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Fourth quarter results were generally in line with our expectations with the exception of higher IV solutions revenues due to the U.S. market shortage.” Revenues by product line for the three and twelve months ended December 31, 2024 and 2023 were as follows (in millions): Three months ended December 31, Twelve months ended December 31, Product Line 2024 2023 $ Change 2024 2023 $ ChangeConsumables $268.1 $254.0 $14.1 $1,038.9 $969.1 $69.8Infusion Systems 171.7 165.1 6.6 652.4 629.0 23.4Vital Care* 190.0 168.7 21.3 690.7 661.0 29.7Total** $629.8 $587.8 $42.0 $2,382.0 $2,259.1 $122.9 *Vital Care includes Pfizer contract manufacturing revenue of $8.2 million and $46.8 million for the three and twelve months ended December 31, 2024, respectively, as compared to $12.1 million and $45.7 million for the three and twelve months ended December 31, 2023.** Totals may differ from the income statement due to the rounding of product lines. Fiscal Year 2025 Guidance For fiscal year 2025 the Company estimates GAAP net loss to be in the range of $(45) million to $(28) million and GAAP net loss per share estimated to be in the range of $(1.81) to $(1.11). For the fiscal year 2025, excluding the potential impact from the Company's previously announced IV Solutions joint venture transaction, the Company expects adjusted EBITDA to be in the range of $395 million to $425 million, and adjusted EPS to be in the range of $6.55 to $7.25. The Company anticipates the IV Solutions joint venture will close during the second quarter of 2025 and, if so, is expected to reduce the 2025 adjusted EBITDA guidance by $15 million to $20 million and be neutral to adjusted EPS. Conference Call The Company will host a conference call to discuss its fourth quarter 2024 financial results, today at 4:30 p.m. ET (1:30 p.m. PT). The call can be accessed at (800) 445-7795, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on Event Calendar and clicking on the Webcast icon and following the prompts. The webcast will also be available by replay. About ICU Medical ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as ''will,'' ''expect,'' ''believe,'' ''could,'' ''would,'' ''estimate,'' ''continue,'' ''build,'' ''expand'' or the negative thereof or comparable terminology and may include (without limitation) information regarding the Company's expectations, goals and intentions regarding the future and financial outlook for 2025 and expected impacts from the IV Solutions joint venture. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the Company and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s ability to compete successfully; decreased demand for the Company's products; costs related to product development; cost volatility or loss of supply of raw materials; inflation, tariffs and foreign currency exchange rates; impacts from global macroeconomic and geopolitical conditions; healthcare costs and reimbursement levels; disruptions at the FDA and other governmental agencies; damage at the Company’s manufacturing or supply facilities; risks associated with the IV Solutions joint venture; and the other important factors described under “Risk Factors” in the Company's Quarterly Reports on Form 10-Q for the quarterly period ended September 30, 2024, as such factors may be updated from time to time in the Company’s reports filed with the SEC, including without limitation its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise unless required by law. ICU MEDICAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(In thousands) December 31,2024 December 31,2023 ASSETS CURRENT ASSETS: Cash and cash equivalents$308,566 $254,222 Short-term investment securities — 501 TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES 308,566 254,723 Accounts receivable, net of allowance for doubtful accounts 182,828 161,566 Inventories 584,676 709,360 Prepaid income taxes 11,244 21,983 Prepaid expenses and other current assets 70,287 73,640 Assets held for sale 284,382 — TOTAL CURRENT ASSETS 1,441,983 1,221,272 PROPERTY, PLANT AND EQUIPMENT, net 442,746 612,909 OPERATING LEASE RIGHT-OF-USE ASSETS 53,295 69,909 GOODWILL 1,432,772 1,472,446 INTANGIBLE ASSETS, net 740,789 870,588 DEFERRED INCOME TAXES 24,211 37,295 OTHER ASSETS 68,135 94,020 TOTAL ASSETS$4,203,931 $4,378,439 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable$148,020 $150,030 Accrued liabilities 306,923 268,215 Current portion of long-term debt 51,000 51,000 Income tax payable 17,328 7,714 Contingent earn-out liability — 4,879 Liabilities held for sale 32,911 — TOTAL CURRENT LIABILITIES 556,182 481,838 CONTINGENT EARN-OUT LIABILITY — 3,991 LONG-TERM DEBT 1,531,858 1,577,770 OTHER LONG-TERM LIABILITIES 66,745 100,497 DEFERRED INCOME TAXES 48,814 55,873 INCOME TAX LIABILITY 35,097 35,060 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY: Convertible preferred stock, $1.00 par value; Authorized — 500 shares; Issued and outstanding — none — — Common stock, $0.10 par value; Authorized — 80,000 shares; Issued —24,518 and 24,144 shares at December 31, 2024 and December 31, 2023, respectively, and outstanding — 24,517 and 24,141 shares at December 31, 2024 and December 31, 2023, respectively 2,452 2,414 Additional paid-in capital 1,412,118 1,366,493 Treasury stock, at cost (92) (262)Retained earnings 690,158 807,846 Accumulated other comprehensive loss (139,401) (53,081)TOTAL STOCKHOLDERS' EQUITY 1,965,235 2,123,410 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$4,203,931 $4,378,439 ICU MEDICAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)(In thousands, except per share data) Three months ended December 31, Twelve months ended December 31, 2024 2023 2024 2023 TOTAL REVENUES$629,805 $587,856 $2,382,046 $2,259,126 COST OF GOODS SOLD 402,547 416,271 1,557,264 1,519,253 GROSS PROFIT 227,258 171,585 824,782 739,873 OPERATING EXPENSES: Selling, general and administrative 158,849 154,617 638,762 606,693 Research and development 22,355 22,411 88,615 85,344 Restructuring, strategic transaction and integration 9,771 10,731 59,840 41,258 Change in fair value of contingent earn-out (1,408) (3,991) (5,399) (16,247)TOTAL OPERATING EXPENSES 189,567 183,768 781,818 717,048 INCOME (LOSS) FROM OPERATIONS 37,691 (12,183) 42,964 22,825 INTEREST EXPENSE, net (23,457) (24,408) (95,753) (95,219)OTHER EXPENSE, net (6,017) (90) (13,223) (5,905)INCOME (LOSS) BEFORE INCOME TAXES 8,217 (36,681) (66,012) (78,299)(PROVISION) BENEFIT FOR INCOME TAXES (32,045) 19,534 (51,676) 48,644 NET LOSS$(23,828) $(17,147) $(117,688) $(29,655)NET LOSS PER SHARE Basic$(0.97) $(0.71) $(4.83) $(1.23)Diluted$(0.97) $(0.71) $(4.83) $(1.23)WEIGHTED AVERAGE NUMBER OF SHARES Basic 24,492 24,140 24,388 24,091 Diluted 24,492 24,140 24,388 24,091 ICU MEDICAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)(In thousands) Twelve months ended December 31, 2024 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss$(117,688) $(29,655)Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization 219,512 228,774 Noncash lease expense 21,344 21,910 Provision for doubtful accounts 5,800 838 Provision for warranty, returns and field action 1,130 21,582 Stock compensation 46,883 40,563 Loss on disposal of property, plant and equipment and other assets 2,522 2,109 Debt issuance costs amortization 6,807 6,814 Change in fair value of contingent earn-out liability (5,399) (16,247)Usage of spare parts 18,298 17,050 Other 7,393 8,066 Changes in operating assets and liabilities, net of amounts acquired: Accounts receivable (46,844) 48,635 Inventories 16,829 (6,079)Prepaid expenses and other current assets (8,829) 11,672 Other assets (23,154) (24,695)Accounts payable 12,531 (68,301)Accrued liabilities 20,668 (14,479)Income taxes, including excess tax benefits and deferred income taxes 26,230 (82,356)Net cash provided by operating activities 204,033 166,201 CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property, plant and equipment (79,373) (83,893)Proceeds from sale of assets 746 1,501 Intangible asset additions (10,833) (9,777)Proceeds from sale and maturities of investment securities 500 4,222 Net cash used in investing activities (88,960) (87,947)CASH FLOWS FROM FINANCING ACTIVITIES: Principal repayments of long-term debt (51,000) (29,688)Proceeds from exercise of stock options 10,939 4,022 Payments on finance leases (1,147) (963)Payments of contingent earn-out liability (2,600) — Tax withholding payments related to net share settlement of equity awards (11,992) (9,350)Net cash used in financing activities (55,800) (35,979)Effect of exchange rate changes on cash (4,929) 3,163 NET INCREASE IN CASH AND CASH EQUIVALENTS 54,344 45,438 CASH AND CASH EQUIVALENTS, beginning of period 254,222 208,784 CASH AND CASH EQUIVALENTS, end of period$308,566 $254,222 Use of Non-GAAP Financial Information This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). The non-GAAP financial measures should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. There are material limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled non-GAAP financial measures used by other companies, including peer companies. Our management believes that the non-GAAP data provides useful supplemental information to management and investors regarding our performance and facilitates a more meaningful comparison of results of operations between current and prior periods. We use non-GAAP financial measures in addition to and in conjunction with GAAP financial measures to analyze and assess the overall performance of our business, in making financial, operating and planning decisions, and in determining executive incentive compensation. The non-GAAP financial measures include adjusted EBITDA, adjusted revenue, adjusted gross profit, adjusted selling, general and administrative, adjusted research and development, adjusted restructuring, strategic transaction and integration, adjusted change in fair value of contingent earn-out, adjusted income (loss) from operations, adjusted other expense, net, adjusted income (loss) before income taxes, adjusted (provision) benefit for income taxes, adjusted net (loss) income and adjusted diluted (loss) earnings per share, all of which exclude special items because they are highly variable or unusual and impact year-over-year comparisons. For the three months ended December 31, 2024 and 2023, special items include the following: Contract manufacturing: We manufacture certain products for Pfizer in accordance with a manufacturing services agreement. We do not include the contract revenue in our adjusted revenue as the commercial relationship under this agreement was originally negotiated contemporaneously with a business combination and is not indicative of a normal market transaction. Stock compensation expense: Stock-based compensation is generally fixed at the time the stock-based instrument is granted and amortized over a period of several years. The value of stock options is determined using a complex formula that incorporates factors, such as market volatility, that are beyond our control. The value of our restricted stock awards is determined using the grant date stock price, which may not be indicative of our operational performance over the expense period. Additionally, in order to establish the fair value of performance-based stock awards, which are currently an element of our ongoing stock-based compensation, we are required to apply judgment to estimate the probability of the extent to which performance objectives will be achieved. Based on the above factors, we believe it is useful to exclude stock-based compensation in order to better understand our operating performance. Intangible asset amortization expense: We do not acquire businesses or capitalize certain patent costs on a predictable cycle. The amount of purchase price allocated to intangible assets and the term of amortization can vary significantly and are unique to each acquisition. Capitalized patent costs can vary significantly based on our current level of development activities. We believe that excluding amortization of intangible assets provides the users of our financial statements with a consistent basis for comparison across accounting periods. Depreciation expense reduction - Assets Held For Sale Classification: Once classified as held for sale, depreciation expense is not recorded for any long-lived assets included in the disposal group even though these assets continue to be utilized in the normal course of business. As such, we adjust for the impact of the discontinuation of depreciation with respect to assets classified as held for sale during the period as these unique transactions may limit the comparability of our ongoing operations with prior and future periods. Restructuring, strategic transaction and integration: We incur restructuring and strategic transaction charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our ongoing business. Although these events are reflected in our GAAP financial statements, these unique transactions may limit the comparability of our ongoing operations with prior and future periods. Change in fair value of contingent earn-out: We exclude the impact of certain amounts recorded in connection with business combinations. We exclude items that are either non-cash or not normal, recurring operating expenses due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing. Quality system and product-related remediation: We exclude certain quality system and product-related remediation charges in determining our non-GAAP financial measures as they may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance. Legal settlement: Occasionally, we are involved in legal proceedings that may result in one-time legal settlements. We exclude these settlements as they have no direct correlation to the operation of our ongoing business. Asset write-offs and similar charges: Occasionally, we may write-off certain assets or we may sell certain assets. We exclude the non-cash gain/loss on the write-off/sale of these assets in determining our non-GAAP financial measures as they may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance. From time to time in the future, there may be other items that we may exclude if we believe that doing so is consistent with the goal of providing useful information to investors and management. In addition to the above special items, Adjusted EBITDA additionally excludes the following items from net income: Depreciation expense: We exclude depreciation expense in deriving adjusted EBITDA because companies utilize productive assets of different ages and the depreciable lives can vary significantly resulting in considerable variability in depreciation expense among companies. Interest, net: We exclude interest in deriving adjusted EBITDA as interest can vary significantly among companies depending on a company's level of income generating instruments and/or level of debt. Taxes: We exclude taxes in deriving adjusted EBITDA as taxes are deemed to be non-core to the business and may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance. Adjusted Diluted EPS excludes from diluted EPS, net of tax, the special items listed above. The tax effect on the special items is calculated using the specific tax rate applied to each adjustment based on the nature of the item/or the tax jurisdiction in which the item has been recorded. Additionally, adjusted diluted EPS may exclude the income tax impact of certain non-recurring discrete tax items that are not reflective of income tax expense/benefit incurred as a result of current period earnings/ loss, as well as the impact of certain deferred tax valuation allowances when assessed against non-GAAP profitability. We also present Free cash flow as a non-GAAP financial measure as management believes that this is an important measure for use in evaluating overall company financial performance as it measures our ability to generate additional cash flow from business operations. Free cash flow should be considered in addition to, rather than as a substitute for, net income as a measure of our performance or net cash provided by operating activities as a measure of our liquidity. Additionally, our definition of free cash flow is limited and does not represent residual cash flows available for discretionary expenditures due to the fact that the measure does not deduct the payments required for debt service and other obligations or payments made for business acquisitions. Therefore, we believe it is important to view free cash flow as supplemental to our entire statement of cash flows. The following tables reconcile our non-GAAP financial measures for the periods presented: ICU MEDICAL, INC. AND SUBSIDIARIESReconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(In thousands, except per share data) Adjusted EBITDA Three months endedDecember 31, 2024 2023 GAAP net loss$(23,828) $(17,147) Non-GAAP adjustments: Interest, net 23,457 24,408 Stock compensation expense 12,517 10,685 Depreciation and amortization expense 52,993 57,159 Restructuring, strategic transaction and integration 9,771 10,731 Change in fair value of contingent earn-out (1,408) (3,991)Quality system and product-related charges (32) 24,003 Asset write-offs and similar charges — (48)Provision (Benefit) for income taxes 32,045 (19,534)Total non-GAAP adjustments 129,343 103,413 Adjusted EBITDA$105,515 $86,266 ICU MEDICAL, INC. AND SUBSIDIARIESReconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(In thousands, except percentages and per share) The Company’s U.S. GAAP results for the three months ended December 31, 2024 included special items which impacted the U.S. GAAP measures as follows: Total revenuesGross profitSelling, general and administrativeResearch and developmentRestructuring, strategic transaction and integrationChange in fair value of contingent earn-out Income from operationsIncome before income taxesProvision for income taxesNet (loss) incomeDiluted (loss) earnings per shareReported (GAAP)$629,805 $227,258 $158,849 $22,355 $9,771 $(1,408)$37,691 $8,217 $(32,045)$(23,828)$(0.97)Reported percent of total revenues (or percent of (loss) income before income taxes for benefit (provision) for income taxes) 36% 25% 4% 2% —% 6% 1% 390.0%(4)% Contract manufacturing (8,181) — — — — — — — — — Stock compensation expense — 1,721 (10,090) (706) — — 12,517 12,517 (3,004) 9,513 0.39 Amortization expense — 1,038 (32,794) — — — 33,832 33,832 (8,220) 25,612 1.04 Depreciation expense reduction - assets held for sale classification — (2,149) — — — — (2,149) (2,149) 516 (1,633) (0.07)Restructuring, strategic transaction and integration — — — — (9,771) — 9,771 9,771 (4,745) 5,026 0.20 Change in fair value of contingent earn-out — — — — — 1,408 (1,408) (1,408) — (1,408) (0.06)Quality system and product-related remediation — (32) — — — — (32) (32) 36 4 — Tax expense from valuation allowance* — — — — — — — — 38,789 38,789 1.57 Adjusted (Non-GAAP)**$621,624 $227,836 $115,965 $21,649 $— $— $90,222 $60,748 $(8,673)$52,075 $2.11 Adjusted percent of total revenues (or percent of (loss) income before income taxes for benefit (provision) for income taxes) 37% 19% 3% —% —% 15% 10% 14.3% 8% _______________________ * The Company’s non-GAAP annual effective tax rate is calculated without the tax expense related to the valuation allowance against certain U.S. Federal and State deferred tax assets. The valuation allowance was recorded based on an assessment of available positive and negative evidence, including, predominantly, an estimate that we will be in a three-year cumulative U.S. loss position on a GAAP basis as of December 31, 2024. However, based on the same assessment, including, predominantly, our being, in a three-year cumulative U.S. income position on a non-GAAP basis, which excludes the impact of our non-GAAP adjustments, we concluded that recording a valuation allowance would not have been appropriate for non-GAAP reporting. As a result, the tax expense for the valuation allowance was added back to our calculation of non-GAAP annual effective tax rate.** Amounts may not foot due to rounding. ICU MEDICAL, INC. AND SUBSIDIARIESReconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(continued)(In thousands, except percentages and per share) The Company’s U.S. GAAP results for the three months ended December 31, 2023 included special items which impacted the U.S. GAAP measures as follows: Total revenuesGross profitSelling, general and administrativeResearch and developmentRestructuring, strategic transaction and integrationChange in fair value of contingent earn-out(Loss) income from operationsOther expense, net(Loss) income before income taxesBenefit (provision) for income taxesNet (loss) incomeDiluted (loss) earnings per shareReported (GAAP)$587,856 $171,585 $154,617 $22,411 $10,731 $(3,991)$(12,183)$(90)$(36,681)$19,534 $(17,147)$(0.71)Reported percent of total revenues (or percent of (loss) income before income taxes for benefit (provision) for income taxes) 29% 26% 4% 2%(1)%(2)% —%(6)% 53.3%(3)% Contract manufacturing (12,112) — — — — — — — — — — Stock compensation expense — 1,732 (8,503) (450) — — 10,685 — 10,685 (2,564) 8,121 0.33 Amortization expense — — (33,255) — — — 33,255 — 33,255 (8,139) 25,116 1.03 Restructuring, strategic transaction and integration — — — — (10,731) — 10,731 — 10,731 (2,589) 8,142 0.33 Change in fair value of contingent earn-out — — — — — 3,991 (3,991) — (3,991) — (3,991) (0.16)Quality system and product-related remediation — 24,003 — — — — 24,003 — 24,003 (5,931) 18,072 0.74 Asset write-offs and similar charges — — — — — — — (48) (48) — (48) — Adjusted (Non-GAAP)*$575,744 $197,320 $112,859 $21,961 $— $— $62,500 $(138)$37,954 $311 $38,265 $1.57 Adjusted percent of total revenues (or percent of (loss) income before income taxes for benefit (provision) for income taxes) 34% 20% 4% —% —% 11% —% 7%(0.8)% 7% _____________* Amounts may not foot due to rounding ICU MEDICAL, INC. AND SUBSIDIARIESReconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Unaudited)(In thousands) Three months endedDecember 31, Twelve months endedDecember 31, 2024 2023 2024 2023 Net cash provided by operating activities$40,192 $91,269 $204,033 $166,201 Purchase of property, plant and equipment (24,081) (29,937) (79,373) (83,893)Proceeds from sale of assets 51 20 746 1,501 Free cash flow$16,162 $61,352 $125,406 $83,809 ICU MEDICAL, INC. AND SUBSIDIARIESFiscal Year 2025 Outlook (Unaudited)(In millions, except per share data) Low End of Guidance High End of GuidanceGAAP net loss$(45) $(28) Non-GAAP adjustments: Interest, net 95 95 Stock compensation expense 54 54 Depreciation and amortization expense 217 217 Restructuring, strategic transaction and integration 43 43 Quality and regulatory initiatives and remediation 50 50 Benefit for income taxes (19) (6)Total non-GAAP adjustments$440 $453 Adjusted EBITDA$395 $425 GAAP loss per share$(1.81) $(1.11) Non-GAAP adjustments: Stock compensation expense 2.18 2.18 Amortization expense 5.56 5.56 Restructuring, strategic transaction and integration 1.73 1.73 Quality and regulatory initiatives and remediation 2.02 2.02 Depreciation expense reduction - assets held for sale classification (0.48) (0.48)Estimated income tax impact from adjustments (2.65) (2.65)Adjusted earnings per share$6.55 $7.25 CONTACT: ICU Medical, Inc. Brian Bonnell, Chief Financial Officer(949) 366-2183 ICR, Inc.John Mills, Partner(646) 277-1254

ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News